|Bid||11.80 x 50000|
|Ask||11.89 x 81200|
|Day's Range||11.85 - 12.61|
|52 Week Range||2.06 - 12.61|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.